health benefits of glp-1 agonists Drugs & What They Do GLP-1 Receptor Agonists and Research
Description
GLP-1 helped reduce cravings and gave me more control over my meals
2022;14:e21536
These important negative data support the hypothesis that even in a weight-reduced state from peak obesity, the DVC GLP-1R and amylin receptors theoretically remain as continued viable drug targets for sustaining weight loss
3 Key Considerations for Plan Sponsors As you evaluate your plan benefit philosophy, including whether or not to cover the use of these drugs for weight loss, and prioritize what is most important to you, consider three key areas: Coverage, Cost and Care
Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca plc, Sanofi S.A., Merck & Co., Inc., Boehringer Ingelheim International GmbH, and Zealand Pharma A/S are global key players in the market
